Richard P. Baum is Director of the Advanced Theranostics Center for Radiomolecular Precision Oncology, Curanosticum at Deutsche Klinik für Diagnostik (DKD HELIOS Klinik), Wiesbaden, Germany. Professor Baum is also the President of the ICPO Academy, Chairman of the Scientific Board of the ICPO Foundation and previous President of WARMTH (World Association of Radiopharmaceutical and Molecular Therapy) and of the International Research Group on Immuno-Scintigraphy and Therapy (IRIST). He is the co-founder - together with Prof. Frank Rösch - of the Theranostics World Congress (TWC) in 2011.

Thomas Beyer holds a PhD in Physics and is co-developer of the first combined PET/CT system worldwide. He has a background in research and project management in academia and imaging industry.
Thomas graduated in Physics at the Leipzig University (Germany) and got his PhD in Medical Physics from Surrey University (UK). During his US-based studies he became involved in the development and clinical testing of the first PET/CT prototype (1992-2000) before joining Siemens/CTI PET Systems as an International PET/CT specialist. In 2002 he became a Research Associate in Nuclear Medicine and Radiology and PET/CT project manager at Essen University Hospital (Germany). In 2006 he became Teaching Professor (Priv-Doz) for Experimental Nuclear Medicine at Essen, and joined timaq medical imaging Inc, a Zurich-based Imaging CRO. In 2007 he moved to Philips Medical Systems as International Manager Clinical Science Nuclear Medicine. In 2008 he set up a Zurich-based consulting company for expert advise in cross-modality imaging and applications. He is appointed full professor of Physics of Medical Imaging at the Medical University of Vienna from March 2013.
Thomas is a member of various national and international Medicine organizations, a founding member of the European Association of Nuclear Medicine (EANM) Physics Committee and past Head of the New Technology working group at the Association of Imaging Producers and Equipment Suppliers (AIPES).

Ken Herrmann currently acts as Chair of the Department of Nuclear Medicine at the Universitätsklinikum Essen in Germany, Chair of the EANM Oncology & Theranostics Committee, and serves as a Section Editor of the Journal of Nuclear Medicine. Ken’s earlier career found him as a Visiting Assistant Professor promoted to Associate Professor in the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at the University of California Los Angeles in addition to holding his position as Vice Chair of the Department of Nuclear Medicine at the Universitätsklinikum Würzburg. Ken holds a Doctorate Degree from Humboldt Universität Berlin and completed his residency in Nuclear Medicine at Klinikum rechts der Isar, Technische Universität München in addition to his MBA, which he received from the Universität Zürich, Switzerland in 2011.

Dr. Jingjing Zhang obtained her PhD and post-graduate Doctor degree of Medicine (MD) from the Peking Union Medical College, Peking Union Medical College Hospital (PUMCH), Beijing, China, and then practiced as a Nuclear Medicine Physician for 2 years at Peking Union Medical College Hospital. Dr. Zhang completed a 2-year fellowship at the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), United States. She practiced as Nuclear Medicine Clinical & Research Fellow for 2 years at THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Germany. She is now Assistant Professor (Tenure Track) at the Department of Diagnostic Radiology, and an internal joint appointment to the Clinical Imaging Research Centre, Yong Loo Lin School of Medicine, National University of Singapore.

Prof. Dr. Klaus Kopka (HZDR) is radiopharmaceutical chemist and holds a full professorship (W3) for Bioinorganic and Radiopharmaceutical Chemistry at TU Dresden, Germany, which is combined with the directorship of the Institute of Radiopharmaceutical Cancer Research at Helmholtz-Zentrum Dresden-Rossendorf [HZDR]. Between 2013 and 2019 he held a W3 position at Ruprecht-Karls-University of Heidelberg, Germany. At the same time, he was Head of the Division of Radiopharmaceutical Chemistry at German Cancer Research Center [DKFZ]. In 2018 Klaus Kopka was honoured together with his colleagues Michael Eisenhut, Matthias Eder and Uwe Haberkorn with the highly recognized “The Stifterverband Science Award – Erwin Schrödinger Prize” of the Helmholtz Association. His current research interests focus on Radiopharmaceutical Sciences with focus on theranostic radiopharmaceutical drug development which bridges medicinal chemistry on oncological radiotracers with translational research in Nuclear Medicine. He was and still is involved in the development of the theranostic prostate-specific membrane antigen (PSMA)-targeting radiotracers, i.e., PSMA-617, PSMA-914 and PSMA-1007. At HZDR Klaus Kopka concentrates on the discovery of new classes of oncological radiotracers targeting the tumor microenvironment (TME) for early detection and theranostic treatment of cancer [https://www.hzdr.de/db/Cms?pNid=130].

Josh is an internationally recognized advocate for neuroendocrine tumor patients as well as an advocate for integrative oncology, nuclear medicine, and molecular imaging. He is the inaugural chairman of the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) Patient Advocacy Advisory Board, a member of the Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) Board and President of NorCal CarciNET Community. Mr. Mailman has an MBA from the Anderson School of Management at UCLA and has been a technology entrepreneur for more than 20 years.

Cristina Müller is a research group leader at the Center for Radiopharmaceutical Sciences at Paul Scherrer Institute and Private Docent at the ETH Zurich, Switzerland. Her research focuses on the development and preclinical application of novel radioligands for targeting cancer and inflammatory diseases. A particular interest lies in the investigation of emerging radionuclides for radiotheragnostics.

Professor Dr. Vikas Prasad (Ulm) Vikas Prasad is Director Clinical Theranostics, Assoc. Prof. of Radiology, Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University in St Louis. His research work over the last 21 years spans over all aspects of clinical and translation aspects of theranostics and is actively involved in several oncological societies and education.

Dr. Oliver Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 500 peer-reviewed articles, led or co-led multiple national and international clinical studies, including four phase III studies pivotal for FDA approval (samarium 153 EDTMP, cabazitaxel, radium-223, and PSMA-617 Lu-177). He has lectured widely, and at last count has given invited lectures in 33 countries.

He is currently the Associate Dean for Oncology, Medical Director of the Tulane Cancer Center, and serves as the Laborde Professor for Cancer Research at Tulane Medical School with appointments in both the Medicine and Urology Departments.

He has served as the past Chairman of the Department of Defense Prostate Cancer Integration Panel and is the Medical Oncology Chair of the GU committee of NRG. He is also a past member of the National Cancer Institute Board of Scientific Counselors (Clinical Sciences and Epidemiology), founding co-Director of the Louisiana Cancer Research Consortium, and founding Editor-in-Chief for the peer-reviewed journal Clinical Genitourinary Cancer. 

Dr Zan is the Director of Nuclear Theranostics at New York University Langone Health. Her career focus has been excellence in patient care and collaborative effort among disciplines to improve early diagnosis and therapy in challenging diseases. She collaborates with the pancreas cancer team at NYU under PRECEDE Consortium (Pancreatic Cancer Early Detection Consortium) whose members have discovered unique populations of fibroblasts in pancreatic cancer. She is participating in the first national clinical trial studying the accuracy of 68Ga-FAPI46 in pancreas ductal adenocarcinoma.

Dr Zan is aiming to carry the FAP to early pancreatic cancer detection and even beyond to the benefit of patients as a screening tool in those who are at high risk for developing pancreas adenocarcinoma.